# US 2024/0200062 A1 · Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200062 A1
- Document ID: US20240200062A1
- Status: Published application
- Kind: A1
- Application number: 18/281,680
- Filed: 2022-03-11
- Published: 2024-06-20
- Earliest claimed: 2021-03-12
- Assignees: Pepgen Corporation
- Applicants: PepGen Inc.
- Inventors: Caroline GODFREY; Sonia BRACEGIRDLE; Ashling HOLLAND; Smita GUNNOO
- Web page: https://patentgrep.com/patent/US20240200062A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C12N 2310/11: Antisense
- C12N 2310/3233: Morpholino-type ring
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are methods of treating a subject having Duchenne muscular dystrophy. The method includes administration of 1 mg/kg to 60 mg/kg of a conjugate of an oligonucleotide and a peptide covalently bonded or linked via a linker to the oligonucleotide to the subject (e.g., a subject amenable to exon 51 skipping). The peptide including at least one cationic domain including at least 4 amino acid residues and at least one hydrophobic domain including at least 3 amino acid residues, provided that the peptide includes a total of 7 to 40 amino acid residues, and provided that the at least one cationic domain includes a beta-alanine residue in combination with arginine and/or histidine residues. The oligonucleotide including a total of 12 to 40 contiguous nucleobases, wherein at least 12 contiguous nucleobases are complementary to a target sequence in a human dystrophin gene.

## Claims

### Claim 1

A method of treating a subject having Duchenne muscular dystrophy, the method comprising administering 1 mg/kg to 60 mg/kg of a conjugate of an oligonucleotide and a peptide covalently bonded or linked via a linker to the oligonucleotide,
the peptide comprising at least one cationic domain comprising at least 4 amino acid residues and at least one hydrophobic domain comprising at least 3 amino acid residues, provided that the peptide comprises a total of 7 to 40 amino acid residues, and provided that the at least one cationic domain comprises a beta-alanine residue in combination with arginine and/or histidine residues; and
the oligonucleotide comprising a total of 12 to 40 contiguous nucleobases, wherein at least 12 contiguous nucleobases are complementary to a target sequence in a human dystrophin gene.

### Claim 2 (depends on 1)

The method of claim 1, wherein the oligonucleotide comprises a sequence selected from the group consisting of:
(SEQ ID NO: 106)
5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′;
or
(SEQ ID NO: 107)
5′-ACCAGAGUAACAGUCUGAGUAGGAGC-3′;
(SEQ ID NO: 108;
5′-CUCAUACCUUCUGCUUGAUGAUC-3′;
(SEQ ID NO: 109)
5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′;
(SEQ ID NO: 110)
5′-ACAUCAAGGAAGAUGGCAUUUCUAGUUUGG-3′;
(SEQ ID NO: 111)
5′-ACAUCAAGGAAGAUGGCAUUUCUAG-3′;
(SEQ ID NO: 112)
5′-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3′;
(SEQ ID NO: 113)
5′-AUCAUUUUUUCUCAUACCUUCUGCUAG-3′;
(SEQ ID NO: 114)
5′-AUCAUUUUUUCUCAUACCUUCUGCUAGGAGCUAAAAAG-3′;
(SEQ ID NO: 115)
5′-CACCCACCAUCACCCUCUGUG-3′;
(SEQ ID NO: 116)
5′-AUCAUCUCGUUGAUAUCCUCAA-3′;
and their thymine-substitution analogues

### Claim 3 (depends on 1)

The method of claim 1, wherein each cationic domain has length of between 4 and 12 amino acid residues.

### Claim 4 (depends on 3)

The method of claim 3, wherein each cationic domain has length of between 4 and 7 amino acid residues.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein each cationic domain comprises at least 55%, at least 60%, at least 65% at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% cationic amino acids.

### Claim 6 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein each cationic domain comprises at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 60%, at least 65%, at least 70% arginine and/or histidine residues.

### Claim 7 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein each cationic domain comprises one of the following sequences: RBRRBRR (SEQ ID NO: 1), RBRBR (SEQ ID NO: 2), RBRR (SEQ ID NO: 3), RBRRBR (SEQ ID NO: 4), RRBRBR (SEQ ID NO: 5), RBRRB (SEQ ID NO: 6), BRBR (SEQ ID NO: 7), RBHBH (SEQ ID NO: 8), HBHBR (SEQ ID NO: 9), RBRHBHR (SEQ ID NO: 10), RBRBBHR (SEQ ID NO: 11), RBRRBH (SEQ ID NO: 12), HBRRBR (SEQ ID NO: 13), HBHBH (SEQ ID NO: 14), BHBH (SEQ ID NO: 15), BRBSB (SEQ ID NO: 16), BRB[Hyp]B (SEQ ID NO: 17), R[Hyp]H[Hyp]HB (SEQ ID NO: 18), R[Hyp]RR[Hyp]R (SEQ ID NO: 19) or any combination thereof.

### Claim 8 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein each cationic domain comprises or consists of one the following sequences: RBRRBRR (SEQ ID NO: 1), RBRBR (SEQ ID NO: 2), RBRR (SEQ ID NO: 3), RBRRBR (SEQ ID NO: 4), RRBRBR (SEQ ID NO: 5), RBRRB (SEQ ID NO: 6), BRBR (SEQ ID NO: 7), RBHBH (SEQ ID NO: 8), HBHBR (SEQ ID NO: 9), RBRHBHR (SEQ ID NO: 10), RBRBBHR (SEQ ID NO:

### Claim 9 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the peptide comprises two cationic domains.

### Claim 10 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein each hydrophobic domain has a length of 3 to 6 amino acids, preferably each hydrophobic domain has a length of 5 amino acids.

### Claim 11

, RBRRBH (SEQ ID NO: 12), HBRRBR (SEQ ID NO: 13), HBHBH (SEQ ID NO: 14), BHBH (SEQ ID NO: 15), BRBSB (SEQ ID NO: 16), BRB[Hyp]B (SEQ ID NO: 17), R[Hyp]H[Hyp]HB (SEQ ID NO: 18), R[Hyp]RR[Hyp]R (SEQ ID NO: 19) or any combination thereof.

### Claim 11 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein each hydrophobic domain comprises at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% hydrophobic amino acids.

### Claim 11

, RBRRBH (SEQ ID NO: 12), HBRRBR (SEQ ID NO: 13), HBHBH (SEQ ID NO: 14), BHBH (SEQ ID NO: 15), BRBSB (SEQ ID NO: 16), BRB[Hyp]B (SEQ ID NO: 17), R[Hyp]H[Hyp]HB (SEQ ID NO: 18), and R[Hyp]RR[Hyp]R (SEQ ID NO: 19).

### Claim 12 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein each hydrophobic domain comprises phenylalanine, leucine, Isoleucine, tyrosine, tryptophan, proline, and/or glutamine residues; preferably wherein each hydrophobic domain comprises or consists of phenylalanine, leucine, isoleucine, tyrosine, tryptophan, proline, and/or glutamine residues.

### Claim 13 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the peptide comprises one hydrophobic domain.

### Claim 14 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the or each hydrophobic domain comprises one of the following sequences: YQFLI (SEQ ID NO: 20), FQILY (SEQ ID NO: 21), ILFQY (SEQ ID NO: 22), FQIY (SEQ ID NO: 23), WWW, WWPWW (SEQ ID NO: 24), WPWW (SEQ ID NO: 25), WWPW (SEQ ID NO: 26) or any combination thereof.

### Claim 15 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the or each hydrophobic domain comprises or consists of one of the following sequences: YQFLI (SEQ ID NO: 20), FQILY (SEQ ID NO: 21), ILFQY (SEQ ID NO: 22), FQIY (SEQ ID NO: 23), WWW, WWPWW (SEQ ID NO: 24), WPWW (SEQ ID NO: 25), WWPW (SEQ ID NO: 26) or any combination thereof.

### Claim 16 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the peptide comprises or consists of two cationic domains and one hydrophobic domain.

### Claim 17 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the peptide comprises or consists of one hydrophobic core domain flanked by two cationic arm domains.

### Claim 18 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the peptide comprises or consists of one hydrophobic core domain comprising a sequence selected from: YQFLI (SEQ ID NO: 20), FQILY (SEQ ID NO: 21), ILFQY (SEQ ID NO: 22), FQIY (SEQ ID NO: 23), WWW, WWPWW (SEQ ID NO: 24), WPWW (SEQ ID NO: 25), and WWPW (SEQ ID NO: 26), flanked by two cationic arm domains each comprising a sequence selected from: RBRRBRR (SEQ ID NO: 1), RBRBR (SEQ ID NO: 2), RBRR (SEQ ID NO: 3), RBRRBR (SEQ ID NO: 4), RRBRBR (SEQ ID NO: 5), RBRRB (SEQ ID NO: 6), BRBR (SEQ ID NO: 7), RBHBH (SEQ ID NO: 8), HBHBR (SEQ ID NO: 9), RBRHBHR (SEQ ID NO: 10), RBRBBHR (SEQ ID NO:

### Claim 19 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the peptide comprises or consists of one of the following sequences: RBRRBRRFQILYRBRBR (SEQ ID NO: 27), RBRRBRRYQFLIRBRBR (SEQ ID NO:

### Claim 20 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the peptide has the following amino acid sequence RBRRBRFQILYBRBR (SEQ ID NO: 35).

### Claim 21 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the peptide has the following amino acid sequence RBRRBRRFQILYRBHBH (SEQ ID NO: 37).

### Claim 22 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the peptide has the following amino acid sequence RBRRBRFQILYRBHBH (SEQ ID NO: 44).

### Claim 23 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the peptide is bonded to the rest of the conjugate through its N-terminus.

### Claim 24 (depends on 23)

The method of claim 23, wherein the C-terminus of the peptide is —NH2.

### Claim 25 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the peptide is bonded to the rest of the conjugate through its C-terminus.

### Claim 26 (depends on 25)

The method of claim 25, wherein the peptide is acylated at its N-terminus.

### Claim 27 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the conjugate comprises or is of the following structure:
[peptide]-[linker]-[oligonucleotide]

### Claim 28 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the conjugate comprises or is of the following structure:

### Claim 29 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the conjugate comprises or is of the following structure:
[peptide]-[linker]-[peptide]-[linker]-[oligonucleotide].

### Claim 30 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein each linker is independently of formula (I):
T1—(CR1R2)n—T2. (I)
wherein
T1 is a divalent group for attachment to the peptide and is selected from the group consisting of —NH— and carbonyl;
T2 is a divalent group for attachment to an oligonucleotide and is selected from the group consisting of —NH- and carbonyl;
n is 1, 2 or 3;
each R1 is independently —Y1 —X1 —Z1,
wherein
Y1 is absent or —(CRA1RA2)m—, wherein m is 1, 2, 3 or 4, and RA1 and RA2 are each independently hydrogen, OH, or (1-2C)alkyl;
X1 is absent, —O—, —C(O)—, —C(O)O—, —OC(O)—, —CH(ORA3)—, —N(RA3)—, —N(RA3)—C(O)—, —N(RA3)—C(O)O—, —C(O)—N(RA3)—, —N(RA3)C(O)N(RA3)—, —N(RA3)C(N RA3)N(RA3)—, —SO—, —S—, —SO2—, —S(O)2N(RA3)—, or —N(RA3)SO2—, wherein each RA3 is independently selected from hydrogen and methyl; and
Z1 is a further oligonucleotide or is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, or heteroaryl,
wherein each (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, and heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituent groups selected from the group consisting of (1-4C) alkyl, oxo, halo, cyano, nitro, hydroxy, carboxy, NRA4 RA5, and (1-4C)alkoxy, wherein RA4 and RA5 are each independently selected from the group consisting of hydrogen and (1-4C)alkyl; and
each R2 is independently —Y2—X2—Z2, wherein
Y2 is absent or a group of the formula —[CRB1 RB2]n— in which m is an integer selected from 1, 2, 3 or 4, and RB1 and RB2 are each independently selected from hydrogen, OH or (1-2C)alkyl;
X2 is absent, —O—, —C(O)—, —C(O)O—, —OC(O)—, —CH(ORB3)—, —N(RB3)—, —N(RB3)—C(O)—, —N(RB3)—C(O)O—, —C(O)—N(RB3)—, —N(RB3)C(O)N(RB3)—, —N(RB3)C(NRB3)N(RB3)—, —SO—, —S— —SO2—, —S(O)2N(RB3)—, or —N(RB3)—SO2—, wherein each RB3 is independently selected from hydrogen or methyl; and
Z2 is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl or heteroaryl, wherein each (1-6C)alkyl, (2- 6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl or heteroaryl is optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituent groups selected from the group consisting of (1-4C) alkyl, oxo, halo, cyano, nitro, hydroxy, carboxy, NRB4 RB5, and (1-4C)alkoxy, wherein RB4 and RB5 are each independently hydrogen or (1-2C)alkyl; with the proviso that; when n=1 and T1 and T2 are different to one another, then R1 and R2 are not both H; when n=1, T1 and T2 are different to one another and one of R1 and R2 is H then the other of R1 and R2 is not methyl; or when n=2 and each occurrence of R1 and R2 is H, then T1 and T2 are both —C(O)- or are both —NH—.

### Claim 31

, RBRRBRRILFQYRBRBR (SEQ ID NO: 32), RBRRBRFQILYBRBR (SEQ ID NO: 35), RBRRBRRFQILYRBHBH (SEQ ID NO: 37), RBRRBRRFQILYHBHBR (SEQ ID NO: 38), and RBRRBRFQILYRBHBH (SEQ ID NO: 44).

### Claim 31 (depends on 30)

The method of claim 30, wherein T2 is —C(O)—.

### Claim 32 (depends on 30)

The method of claim 30, wherein each R1 is independently —Y1 —X1 —Z1, wherein:
Y1is absent or —(CRA1RA2)m—, wherein m is 1, 2, 3 or 4, and RA1 and RA2 are each hydrogen or (1-2C)alkyl;
X1 is absent, —O—, —C(O)- 7 —C(O)O—, —N(RA3)—, —N(RA3)—C(O)—, —C(O)—N(RA3)—, —N(RA3)C(O)N(RA3)—, —N(RA3)C(N RA3)N(RA3)- or—S—, wherein each RA3 is independently hydrogen or methyl; and
Z1 is a further oligonucleotide or is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, or heteroaryl, wherein each (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, and heteroaryl is optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituent groups selected from the group consisting of (1-4C) alkyl, oxo, halo, cyano, nitro, hydroxy, carboxy, NRA4 RA5, and (1-4C)alkoxy, wherein RM and RA5 are each independently hydrogen or (1-2C)alkyl.

### Claim 33 (depends on 30)

The method of claim 30, wherein each R1 is independently —Y1 —X1 —Z1, wherein:
Y1is absent or —(CRA1RA2)m—, wherein m is 1, 2, 3, or 4, and RA1 and R″ are each independently hydrogen or (1-2C)alkyl;
X1 is absent, —O—, —C(O)—, —C(O)O—, —N(RA3)—, —N(RA3)—C(O)—, —C(O)—N(RA3)—, —N(RA3)C(O)N(RA3)—, —N(RA3)C(NRA3)N(RA3)—, or—S—, wherein each RA3 is independently hydrogen or methyl; and
Z1 is a further oligonucleotide or is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, or heteroaryl, wherein each (1-6C)alkyl, aryl, (3-6C)cycloalkyl, and heteroaryl is optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituent groups selected from the group consisting of (1-4C) alkyl, halo, and hydroxy.

### Claim 34 (depends on 30)

The method of claim 30, wherein each R1 is independently 7 wherein:
Y1 is absent or a group of the formula —(cRA1RA2)m—, wherein m is 1, 2, 3 or 4, and RA1 and RA2 are each independently hydrogen or (1-2C)alkyl;
X1 is absent, —C(O)—, —C(O)O—, —N(RA3)—C(O)—, —C(O)—N(RA3)—, wherein each RA3 is hydrogen or methyl; and
Z1 is a further oligonucleotide or is hydrogen, (1- 6C)alkyl, aryl, (3-6C)cycloalkyl, or heteroaryl, wherein each (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, and heteroaryl is optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituent groups selected from the group consisting of (1-4C) alkyl, halo, and hydroxy.

### Claim 35 (depends on 30)

The method of claim 30, wherein each R1 is independently —Y1—X1—Z1, wherein:
Y1 is absent, —(CH2)—, or —(CH2CH2)—;
X1 is absent, —N(RA3)—C(O)—, —C(O)—N(RA3)—, wherein each RA3 is independently hydrogen or methyl; and
Z1 is hydrogen or (1-2C)alkyl.

### Claim 36 (depends on 30)

The method of claim 30, wherein each R2 is independently —Y2—Z2,
wherein Y2 is absent or —(CRB1 RB2 RB2) m—, wherein m is 1, 2, 3 or 4, and RB1 and RB2 are each independently hydrogen or (1-2C)alkyl; and
Z2 is hydrogen or (1-6C)alkyl.

### Claim 37 (depends on 30)

The method of claim 30, wherein each R2 is hydrogen.

### Claim 38 (depends on 30)

The method of claim 30, wherein n is 2 or 3.

### Claim 39 (depends on 30)

The method of claim 30, wherein n is 1.

### Claim 40 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the linker is an amino acid residue selected from the group consisting of glutamic acid, succinic acid, and gamma-aminobutyric acid residues.

### Claim 41 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the linker is of the following structure:

### Claim 42 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the linker is of the following structure:

### Claim 43 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the linker is of the following structure:

### Claim 44 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the linker is of the following structure:

### Claim 45 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the linker is of the following structure:

### Claim 46 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the conjugate comprises or is of the following structure:

### Claim 47 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the conjugate comprises or is of the following structure:

### Claim 48 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the conjugate comprises or is of the following structure:

### Claim 49 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the conjugate comprises or is of the following structure:

### Claim 50 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the conjugate comprises or is of the following structure:

### Claim 51 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the oligonucleotide is bonded to the linker or the peptide at its 3′ terminus.

### Claim 52 (depends on 1)

The method of claim 1, wherein the conjugate comprises or consists of 5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′ (SEQ ID NO: 106), 5′-ACCAGAGUAACAGUCUGAGUAGGAGC-3′ (SEQ ID NO: 107), 5′-CUCAUACCUUCUGCUUGAUGAUC-3′ (SEQ ID NO: 108), 5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′ (SEQ ID NO: 109), 5′-ACAUCAAGGAAGAUGGCAUUUCUAGUUUGG-3′ (SEQ ID NO: 110), 5′-ACAUCAAGGAAGAUGGCAUUUCUAG-3′ (SEQ ID NO: 111), 5′-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3′ (SEQ ID NO: 112), 5′-AUCAUUUUUUCUCAUACCUUCUGCUAG-3′ (SEQ ID NO: 113), 5′-AUCAUUUUUUCUCAUACCUUCUGCUAGGAGCUAAAAAG-3′ (SEQ ID NO: 114), 5′-CACCCACCAUCACCCUCUGUG-3′ (SEQ ID NO: 115), or 5′-AUCAUCUCGUUGAUAUCCUCAA-3′ (SEQ ID NO: 116), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a glutamic acid residue to C-terminus of peptide Ac-RBRRBRFQILYBRBR, wherein free —COOH, if any, in the glutamic acid residue is replaced with —CONH2.

### Claim 53 (depends on 52)

The method of claim 52, wherein the conjugate comprises or consists of 5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′ (SEQ ID NO: 106) having a 3′-terminus covalently linked via a glutamic acid residue to C-terminus of peptide Ac-RBRRBRFQILYBRBR, wherein free —COOH, if any, in the glutamic acid residue is replaced with —CONH2.

### Claim 54 (depends on 52)

The method of claim 52, wherein the conjugate comprises or consists of 5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′ (SEQ ID NO: 109), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a glutamic acid residue to C-terminus of peptide Ac-RBRRBRFQILYBRBR, wherein free —COOH, if any, in the glutamic acid residue is replaced with —CONH2.

### Claim 55 (depends on 52)

The method of claim 52, wherein the conjugate comprises or consists of 5′-CACCCACCAUCACCCUCUGUG-3′ (SEQ ID NO: 115), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a glutamic acid residue to C-terminus of peptide Ac-RBRRBRFQILYBRBR, wherein free —COOH, if any, in the glutamic acid residue is replaced with —CONH2.

### Claim 56 (depends on 1)

The method of claim 1, wherein the conjugate comprises or consists of 5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′ (SEQ ID NO: 106), 5′-ACCAGAGUAACAGUCUGAGUAGGAGC-3′ (SEQ ID NO: 107), 5′-CUCAUACCUUCUGCUUGAUGAUC-3′ (SEQ ID NO: 108), 5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′ (SEQ ID NO: 109), 5′-ACAUCAAGGAAGAUGGCAUUUCUAGUUUGG-3′ (SEQ ID NO: 110), 5′-ACAUCAAGGAAGAUGGCAUUUCUAG-3′ (SEQ ID NO: 111), 5′-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3′ (SEQ ID NO: 112), 5′-AUCAUUUUUUCUCAUACCUUCUGCUAG-3′ (SEQ ID NO: 113), 5′-AUCAUUUUUUCUCAUACCUUCUGCUAGGAGCUAAAAAG-3′ (SEQ ID NO: 114), 5′-CACCCACCAUCACCCUCUGUG-3′ (SEQ ID NO: 115), or 5′-AUCAUCUCGUUGAUAUCCUCAA-3′ (SEQ ID NO: 116), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a glutamic acid residue to N-terminus of peptide RBRRBRFQILYBRBR—NH2, wherein free —COOH, if any, in the glutamic acid residue is replaced with —CONH2.

### Claim 57 (depends on 56)

The method of claim 56, wherein the conjugate comprises or consists of 5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′ (SEQ ID NO: 106) having a 3′-terminus covalently linked via a glutamic acid residue to N-terminus of peptide RBRRBRFQILYBRBR—NH2, wherein free —COOH, if any, in the glutamic acid residue is replaced with —CONH2.

### Claim 58 (depends on 56)

The method of claim 56, wherein the conjugate comprises or consists of 5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′ (SEQ ID NO: 109), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a glutamic acid residue to N-terminus of peptide RBRRBRFQILYBRBR—NH2, wherein free —COOH, if any, in the glutamic acid residue is replaced with —CONH2.

### Claim 59 (depends on 56)

The method of claim 56, wherein the conjugate comprises or consists of 5′-CACCCACCAUCACCCUCUGUG-3′ (SEQ ID NO: 115), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a glutamic acid residue to N-terminus of peptide RBRRBRFQILYBRBR—NH2, wherein free —COOH, if any, in the glutamic acid residue is replaced with —CONH2.

### Claim 60 (depends on 1)

The method of claim 1, wherein the conjugate comprises or consists of 5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′ (SEQ ID NO: 106), 5′-ACCAGAGUAACAGUCUGAGUAGGAGC-3′ (SEQ ID NO: 107), 5′-CUCAUACCUUCUGCUUGAUGAUC-3′ (SEQ ID NO: 108), 5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′ (SEQ ID NO: 109), 5′-ACAUCAAGGAAGAUGGCAUUUCUAGUUUGG-3′ (SEQ ID NO: 110), 5′-ACAUCAAGGAAGAUGGCAUUUCUAG-3′ (SEQ ID NO: 111), 5′-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3′ (SEQ ID NO: 112), 5′-AUCAUUUUUUCUCAUACCUUCUGCUAG-3′ (SEQ ID NO: 113), 5′-AUCAUUUUUUCUCAUACCUUCUGCUAGGAGCUAAAAAG-3′ (SEQ ID NO: 114), 5′-CACCCACCAUCACCCUCUGUG-3′ (SEQ ID NO: 115), or 5′-AUCAUCUCGUUGAUAUCCUCAA-3′ (SEQ ID NO: 116), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via gamma-aminobutyric acid residue to C-terminus of peptide Ac-RBRRBRFQILYRBHBH.

### Claim 61 (depends on 60)

The method of claim 60, wherein the conjugate comprises or consists of 5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′ (SEQ ID NO: 106) having a 3′-terminus covalently linked via gamma-aminobutyric acid residue to C-terminus of peptide Ac-RBRRBRFQILYRBHBH.

### Claim 62 (depends on 60)

The method of claim 60, wherein the conjugate comprises or consists of 5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′ (SEQ ID NO: 109), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via gamma-aminobutyric acid residue to C-terminus of peptide Ac-RBRRBRFQILYRBHBH.

### Claim 63 (depends on 60)

The method of claim 60, wherein the conjugate comprises or consists of 5′-CACCCACCAUCACCCUCUGUG-3′ (SEQ ID NO: 115), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via gamma-aminobutyric acid residue to C-terminus of peptide Ac-RBRRBRFQILYRBHBH.

### Claim 64 (depends on 1)

The method of claim 1, wherein the conjugate comprises or consists of 5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′ (SEQ ID NO: 106), 5′-ACCAGAGUAACAGUCUGAGUAGGAGC-3′ (SEQ ID NO: 107), 5′-CUCAUACCUUCUGCUUGAUGAUC-3′ (SEQ ID NO: 108), 5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′ (SEQ ID NO: 109), 5′-ACAUCAAGGAAGAUGGCAUUUCUAGUUUGG-3′ (SEQ ID NO: 110), 5′-ACAUCAAGGAAGAUGGCAUUUCUAG-3′ (SEQ ID NO: 111), 5′-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3′ (SEQ ID NO: 112), 5′-AUCAUUUUUUCUCAUACCUUCUGCUAG-3′ (SEQ ID NO: 113), 5′-AUCAUUUUUUCUCAUACCUUCUGCUAGGAGCUAAAAAG-3′ (SEQ ID NO: 114), 5′-CACCCACCAUCACCCUCUGUG-3′ (SEQ ID NO: 115), or 5′-AUCAUCUCGUUGAUAUCCUCAA-3′ (SEQ ID NO: 116), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a glutamic acid residue to C-terminus of peptide Ac-RBRRBRFQILYRBHBH, wherein free —COOH, if any, in the glutamic acid residue is replaced with —CONH2.

### Claim 65 (depends on 64)

The method of claim 64, wherein the conjugate comprises or consists of 5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′ (SEQ ID NO: 106) having a 3′-terminus covalently linked via a glutamic acid residue to C-terminus of peptide Ac-RBRRBRFQILYRBHBH, wherein free —COOH, if any, in the glutamic acid residue is replaced with —CONH2.

### Claim 66 (depends on 64)

The method of claim 64, wherein the conjugate comprises or consists of 5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′ (SEQ ID NO: 109), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a glutamic acid residue to C-terminus of peptide Ac-RBRRBRFQILYRBHBH, wherein free —COOH, if any, in the glutamic acid residue is replaced with —CONH2.

### Claim 67 (depends on 64)

The method of claim 64, wherein the conjugate comprises or consists of 5′-CACCCACCAUCACCCUCUGUG-3′ (SEQ ID NO: 115), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a glutamic acid residue to C-terminus of peptide Ac-RBRRBRFQILYRBHBH, wherein free —COON, if any, in the glutamic acid residue is replaced with —CONH2.

### Claim 68 (depends on 1, 2, 3, 4, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claim 1-4 or 52-67, wherein the linker is of the following structure:

### Claim 69 (depends on 1)

The method of claim 1, wherein the conjugate comprises or consists of 5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′ (SEQ ID NO: 106), 5′-ACCAGAGUAACAGUCUGAGUAGGAGC-3′ (SEQ ID NO: 107), 5′-CUCAUACCUUCUGCUUGAUGAUC-3′ (SEQ ID NO: 108), 5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′ (SEQ ID NO: 109), 5′-ACAUCAAGGAAGAUGGCAUUUCUAGUUUGG-3′ (SEQ ID NO: 110), 5′-ACAUCAAGGAAGAUGGCAUUUCUAG-3′ (SEQ ID NO: 111), 5′-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3′ (SEQ ID NO: 112), 5′-AUCAUUUUUUCUCAUACCUUCUGCUAG-3′ (SEQ ID NO: 113), 5′-AUCAUUUUUUCUCAUACCUUCUGCUAGGAGCUAAAAAG-3′ (SEQ ID NO: 114), 5′-CACCCACCAUCACCCUCUGUG-3′ (SEQ ID NO: 115), or 5′-AUCAUCUCGUUGAUAUCCUCAA-3′ (SEQ ID NO: 116), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a beta-alanine residue to C-terminus of peptide Ac-RBRRBRFQILYBRBR.

### Claim 70 (depends on 69)

The method of claim 69, wherein the conjugate comprises or consists of 5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′ (SEQ ID NO: 106) having a 3′-terminus covalently linked via a beta-alanine residue to C-terminus of peptide Ac-RBRRBRFQILYBRBR.

### Claim 71 (depends on 69)

The method of claim 69, wherein the conjugate comprises or consists of 5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′ (SEQ ID NO: 109), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a beta-alanine residue to C-terminus of peptide Ac-RBRRBRFQILYBRBR.

### Claim 72 (depends on 69)

The method of claim 69, wherein the conjugate comprises or consists of 5′-CACCCACCAUCACCCUCUGUG-3′ (SEQ ID NO: 115), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a beta-alanine residue to C-terminus of peptide Ac-RBRRBRFQILYBRBR.

### Claim 73 (depends on 1)

The method of claim 1, wherein the conjugate comprises or consists of 5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′ (SEQ ID NO: 106), 5′-ACCAGAGUAACAGUCUGAGUAGGAGC-3′ (SEQ ID NO: 107), 5′-CUCAUACCUUCUGCUUGAUGAUC-3′ (SEQ ID NO: 108), 5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′ (SEQ ID NO: 109), 5′-ACAUCAAGGAAGAUGGCAUUUCUAGUUUGG-3′ (SEQ ID NO: 110), 5′-ACAUCAAGGAAGAUGGCAUUUCUAG-3′ (SEQ ID NO: 111), 5′-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3′ (SEQ ID NO: 112), 5′-AUCAUUUUUUCUCAUACCUUCUGCUAG-3′ (SEQ ID NO: 113), 5′-AUCAUUUUUUCUCAUACCUUCUGCUAGGAGCUAAAAAG-3′ (SEQ ID NO: 114), 5′-CACCCACCAUCACCCUCUGUG-3′ (SEQ ID NO: 115), or 5′-AUCAUCUCGUUGAUAUCCUCAA-3′ (SEQ ID NO: 116), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a beta-alanine residue to C-terminus of peptide Ac-RBRRBRFQILYRBHBH.

### Claim 74 (depends on 73)

The method of claim 73, wherein the conjugate comprises or consists of 5′-CTCCAACATCAAGGAAGATGGCATTTCTAG-3′ (SEQ ID NO: 106) having a 3′-terminus covalently linked via a beta-alanine residue to C-terminus of peptide Ac-RBRRBRFQILYRBHBH.

### Claim 75 (depends on 73)

The method of claim 73, wherein the conjugate comprises or consists of 5′-UUCUGUCCAAGCCCGGUUGAAAUC-3′ (SEQ ID NO: 109), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a beta-alanine residue to C-terminus of peptide Ac-RBRRBRFQILYRBHBH.

### Claim 76 (depends on 73)

The method of claim 73, wherein the conjugate comprises or consists of 5′-CACCCACCAUCACCCUCUGUG-3′ (SEQ ID NO: 115), or a thymine-substitution analogue thereof, having a 3′-terminus covalently linked via a beta-alanine residue to C-terminus of peptide Ac-RBRRBRFQILYRBHBH.

### Claim 77 (depends on 1, 2, 3, 4, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1-4, 52-67, and 69-76, wherein the oligonucleotide is a morpholino.

### Claim 78 (depends on 77)

The method of claim 77, wherein all morpholino internucleoside linkages are —P(O)(NMe2)O—.

### Claim 79 (depends on 78)

The method of claim 78, wherein the oligonucleotide comprises the following group as its 5′ terminus:

### Claim 80 (depends on 1, 2, 3, 4, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1-4, 52-67, and 69-76, wherein the oligonucleotide comprises the following group as its 5′ terminus:

### Claim 81 (depends on 1, 2, 3, 4, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1-4, 52-67, and 69-76, wherein the conjugate is administered parenterally.

### Claim 82 (depends on 81)

The method of claim 81, wherein the conjugate is administered by infusion.

### Claim 83 (depends on 82)

The method of claim 82, wherein the conjugate is administered by intravenous infusion.

### Claim 84 (depends on 1, 2, 3, 4, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1-4, 52-67, and 69-76, wherein the subject is amenable to exon 51 skipping.

### Claim 85 (depends on 1, 2, 3, 4, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1-4, 52-67, and 69-76, wherein the conjugate is administered to the subject at a frequency that is weekly to quarterly.

### Claim 86 (depends on 1, 2, 3, 4, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1-4, 52-67, and 69-76, wherein the conjugate is administered to the subject at a frequency that is weekly to monthly.

### Claim 87 (depends on 86)

The method of claim 86, wherein the frequency is weekly, biweekly, or monthly.

### Claim 88 (depends on 1, 2, 3, 4, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1-4, 52-67, and 69-76, wherein the frequency is quarterly.

### Claim 89 (depends on 1, 2, 3, 4, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1-4, 52-67, and 69-76, wherein 40 mg/kg to 60 mg/kg, 30 mg/kg to 50 mg/kg, 30 mg/kg to 40 mg/kg, 40 mg/kg to 50 mg/kg, 50 mg/kg to 60 mg/kg, 35 mg/kg to 45 mg/kg, 45 mg/kg to 55 mg/kg, 35 mg/kg to 55 mg/kg, 30 mg/kg to 45 mg/kg, 35 mg/kg to 50 mg/kg, 40 mg/kg to 55 mg/kg, 45 mg/kg to 60 mg/kg, 1 mg/kg to 30 mg/kg, 1 mg/kg to 20 mg/kg, 5 mg/kg to 25 mg/kg, 10 mg/kg to 30 mg/kg, 1 mg/kg to 15 mg/kg, 5 mg/kg to 20 mg/kg, 10 mg/kg to 25 mg/kg, 15 mg/kg to 30 mg/kg, 1 mg/kg to 10 mg/kg, 5 mg/kg to 15 mg/kg, 10 mg/kg to 20 mg/kg, 15 mg/kg to 25 mg/kg, 20 mg/kg to 30 mg/kg, 1 mg/kg to 25 mg/kg, 4 mg/kg to 20 mg/kg, 6 mg/kg to 15 mg/kg, or 8 mg/kg to 10 mg/kg of conjugate is administered.

### Claim 90 (depends on 1, 2, 3, 4, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of claim any one of claims 1-4, 52-67, and 69-76, wherein 1 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 8 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, or 60 mg/kg of conjugate is administered.

### Claim 91 (depends on 90)

The method of claim 90, wherein 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg of conjugate is administered.

### Claim 92 (depends on 1, 2, 3, 4, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1-4, 52-67, and 69-76, wherein the method is for use in treating a cardiac effect of DMD including, e.g., cardiomyopathy (e.g., dilated, hypertrophic, or restrictive cardiomyopathy), heart failure, and/or a cardiac arrhythmia.
